{
    "2018-05-30": [
        [
            {
                "time": "",
                "original_text": "泰格医药：助力HLX01（利妥昔单抗注射液）完成Ⅲ期临床试验",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "HLX01",
                        "利妥昔单抗注射液",
                        "Ⅲ期临床试验"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}